Nerlynx (neratinib) — Medica
Breast cancer – recurrent or metastatic HER2-positive disease
Initial criteria
- age ≥ 18 years
- HER2-positive breast cancer
- EITHER used in combination with capecitabine AND patient has tried at least two prior anti-HER2-based regimens OR used in combination with capecitabine, paclitaxel, or Kadcyla (ado-trastuzumab emtansine) AND patient has brain metastases
Approval duration
1 year